Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Price: 1377.50 pence per Ordinary share.
- Transaction Date: 15 January 2016.
- Transaction Type: Acquisitions of Ordinary shares via dividend re-investment within an Individual Savings Account (ISA).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses specific share acquisitions by insiders.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to regulatory disclosure of insider trading activity.
Important Facts for Investors
- Insider Activity: Sir Andrew Witty, Mr D S Redfern, and Mrs V A Whyte acquired shares on 15 January 2016.
- Connected Person Activity: Lady C Witty (connected to Sir Andrew Witty) also acquired shares on the same date.
- Transaction Mechanism: All acquisitions resulted from the re-investment of dividends paid on 14 January 2016.
- Share Counts: Sir Andrew Witty acquired 152 shares; Mr D S Redfern acquired 23 shares; Mrs V A Whyte acquired 19 shares; Lady C Witty acquired 39 shares.